CDX2 Monoclonal Antibody

Code CSB-MA437110
Size US$384
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Alternative Names
Caudal type homeo box 2; Caudal type homeo box transcription factor 2; Caudal type homeobox 2; Caudal type homeobox protein 2; caudal type homeobox transcription factor 2; Caudal-type homeobox protein 2; CDX 2; CDX 3; CDX-3; Cdx2; CDX2_HUMAN; CDX3;
Raised in
Mouse
Species Reactivity
Human,Monkey,Mouse
Immunogen
Purified recombinant Human CDX2 protein fragments expressed in E.coli
Immunogen Species
Homo sapiens (Human)
Clonality
Monoclonal
Isotype
lgG2b
Clone No.
13C7
Purification Method
Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Form
Purified mouse monoclonal in PBS(pH 7.4)containing with 0.2% sodium azide,50% glycerol.
Tested Applications
ELISA,WB,ICC,IP
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:5000
ICC 1:50-1:200IP:1:200-1:2000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*